Search
Close this search box.

ACT 2024: Stay Ahead With Scantox’s Expanded Toxicology Services

As we approach the 45th Annual American College of Toxicology (ACT) Meeting, Scantox is experiencing a thrilling period of change. With the recent acquisition of Gentronix Limited, we have combined two industry leaders to offer a complete suite of toxicology services. Our active participation as an exhibitor and Platinum Sponsor underlines our commitment to this event and the advancement of the toxicology field.

Join us in Austin, TX, from November 17 to 20 to meet our top business and scientific team and discover how our enhanced capabilities can accelerate your projects.

What This Acquisition Means for You

Integrating Gentronix into Scantox aligns perfectly with our long-standing strategy to support clients beyond acute toxicology work, guiding them through customized IND-enabling packages and into clinical trials. Gentronix, a reputable genetic toxicology laboratory based in Manchester, England, brings specialized expertise that complements Scantox’s established regulatory toxicology offerings.

Specifically, our toxicology services now also include:

Unified Culture and Commitment to Excellence

Joining forces with Gentronix is not just about expanding Scantox’s services. Both teams bring their own expertise, but they’re driven by the same culture and core values: putting the client first, delivering accurate, high-quality data, timely reporting, and ensuring open, responsive communication every step of the way.

Derek McFerran, Gentronix’s CCO, emphasizes, “Scientific and technical engagement is a strong part of what we offer. We’re experts in the field and build client relationships by providing intellectual input to projects and helping to design the right work packages to meet their needs.”

Discover Scantox’s Expertise at ACT 2024

The ACT Annual Meeting is a cornerstone event for toxicology professionals, providing a unique platform to learn about the latest scientific developments and network with industry leaders. Our teams have a strong history of active participation at ACT.

Why Meet Us at ACT 2024?

  • Exclusive Insights: Learn about our full range of preclinical toxicology services, including general toxicology, genetic toxicology assays, and regulatory toxicology solutions, and gain in-depth expertise in discussions with industry leaders.
  • One-on-One Engagement: Meet with our top business executives, including Jeanet Løgsted (CEO Scantox), Andy Brown (CCO Scantox), Laura Hinton (COO Gentronix), and Derek McFerran (CCO Gentronix), to discuss in detail how we can activate solutions for your project needs.
  • Scientific Presentation: Don’t miss our session on How to Obtain Stress-Free Blood Samples in Minipigs,presented by Mikkel Lykke Krarup  (CSO Regulatory Toxicology). This presentation highlights our commitment to innovative and humane research methods, ensuring the well-being of the animals in our studies.

Where You Can Find Us

Although we will have two separate booths due to prior arrangements, our teams will work together seamlessly to provide a unified experience for attendees. Connect with our experts at 

  • Scantox Booth: 514
  • Gentronix Booth: 115

Who Should Connect with Us?

Whether you’re a mid-size to large pharmaceutical company or an emerging biotech firm, we’d love to hear more about your projects. Let’s discuss how we can support you with preclinical assets and validated workflows to advance your drug development programs effectively.

An Invitation To Meet Up

If your organization values a deep understanding of drug development processes and scientific and operational excellence, we invite you to meet our decision-making team.

Don’t miss this opportunity to connect and elevate your toxicology program!